Product Data Sheet

BLU9931



Cat. No.:	A8706
CAS No.:	1538604-68-0
Formula:	C26H22Cl2N4O3
M.Wt:	509.38
Synonyms:	
Target:	Tyrosine Kinase
Pathway:	FGFR
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

⩾50.9 mg/mL in DMSO; insoluble in H2O; ⩾2.53 mg/mL in EtOH with gentle warming and ultrasonic

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	1.9632 mL	9.8159 mL	19.6317 mL
5 mM	0.3926 mL	1.9632 mL	3.9263 mL
10 mM	0.1963 mL	0.9816 mL	1.9632 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	FGFR4 inhibitor,potent and irreversible
IC_{50} & Target	

In Vitro

Cell Viability Assay

Cell Line:	MDA-MB-453, DMS114 and Hep 3B cells
Preparation method:	This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting conditions:	0.3 ~ 300 nM; 1 hr

	Applications:	In MDA-MB-453 cells, BLU9931 dose-dependently and effectively reduced phosphorylation of FGFR4 signaling pathway components, including FRS2, MAPK and AKT. In DMS114 cells, BLU9931 exhibited minimal reduction of phosphorylation in all FGFR1 signaling pathway components. In Hep 3B cells, BLU9931 also potently inhibited phosphorylation of the FGFR4 pathway components (except pAKT).
In Vivo	**Animal experiment**	
	Animal models:	Hep 3B tumor-bearing mice
	Dosage form:	10, 30 and 100 mg/kg; p.o.; b.i.d., for 21 days
	Applications:	BLU9931 dose-dependently inhibited the growth of Hep 3B tumors. At the dose of 100 mg/kg, BLU9931 resulted in tumor regression. Moreover, 2 of the 9 mice showed no signs of tumor 30 days after cessation of treatment.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov. 2015 Apr;5(4):424-37.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com